Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serplulimab + CAPOX + RT in locally advanced colon cancer
NCT05732493Phase 2Unknown
- Sponsor
- Fudan University
- Start
- Mar 2023
- Primary completion
- Dec 2023
- Modality
- Immune Checkpoint Inhibitors
01
Overview
Phase 2, randomised, open-label trial of serplulimab in colon cancer (2 arms), sponsored by Fudan University. Primary endpoint: Pathologic Complete Response. Status: unknown.
02
Drugs
serplulimab
03
Conditions
colon cancer
Beyond the preview
Go deeper on NCT05732493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05732493.